Oral chemotherapy for hormone refractory prostate cancer: The University of Michigan experience

J. M. Kamradt; D. C. Smith; K. J. Pienta

doi:10.1016/S0094-0143(05)70073-2

Oral chemotherapy for hormone refractory prostate cancer: The University of Michigan experience

J. M. Kamradt, D. C. Smith, K. J. Pienta

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

The use of oral chemotherapy for the treatment of malignant disease is expanding. The authors' experience with oral chemotherapy for hormone- refractory prostate cancer continues to grow. These therapies are well- tolerated and effective. Already, these regimens are being improved by hybridizing them with intravenous agents such as paclitaxel. Also, oral novel agents are being tested that may offer new options for the treatment of hormone-refractory prostate cancer.

Original language	English (US)
Pages (from-to)	333-340
Number of pages	8
Journal	Urologic Clinics of North America
Volume	26
Issue number	2
DOIs	https://doi.org/10.1016/S0094-0143(05)70073-2
State	Published - 1999
Externally published	Yes

ASJC Scopus subject areas

Urology

Access to Document

10.1016/S0094-0143(05)70073-2

Cite this

@article{566a9a55ec4548e4866747d302f172b9,

title = "Oral chemotherapy for hormone refractory prostate cancer: The University of Michigan experience",

abstract = "The use of oral chemotherapy for the treatment of malignant disease is expanding. The authors' experience with oral chemotherapy for hormone- refractory prostate cancer continues to grow. These therapies are well- tolerated and effective. Already, these regimens are being improved by hybridizing them with intravenous agents such as paclitaxel. Also, oral novel agents are being tested that may offer new options for the treatment of hormone-refractory prostate cancer.",

author = "Kamradt, {J. M.} and Smith, {D. C.} and Pienta, {K. J.}",

year = "1999",

doi = "10.1016/S0094-0143(05)70073-2",

language = "English (US)",

volume = "26",

pages = "333--340",

journal = "Urologic Clinics of North America",

issn = "0094-0143",

publisher = "W.B. Saunders Ltd",

number = "2",

}

TY - JOUR

T1 - Oral chemotherapy for hormone refractory prostate cancer

T2 - The University of Michigan experience

AU - Kamradt, J. M.

AU - Smith, D. C.

AU - Pienta, K. J.

PY - 1999

Y1 - 1999

N2 - The use of oral chemotherapy for the treatment of malignant disease is expanding. The authors' experience with oral chemotherapy for hormone- refractory prostate cancer continues to grow. These therapies are well- tolerated and effective. Already, these regimens are being improved by hybridizing them with intravenous agents such as paclitaxel. Also, oral novel agents are being tested that may offer new options for the treatment of hormone-refractory prostate cancer.

AB - The use of oral chemotherapy for the treatment of malignant disease is expanding. The authors' experience with oral chemotherapy for hormone- refractory prostate cancer continues to grow. These therapies are well- tolerated and effective. Already, these regimens are being improved by hybridizing them with intravenous agents such as paclitaxel. Also, oral novel agents are being tested that may offer new options for the treatment of hormone-refractory prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=0032912714&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032912714&partnerID=8YFLogxK

U2 - 10.1016/S0094-0143(05)70073-2

DO - 10.1016/S0094-0143(05)70073-2

M3 - Article

C2 - 10361556

AN - SCOPUS:0032912714

SN - 0094-0143

VL - 26

SP - 333

EP - 340

JO - Urologic Clinics of North America

JF - Urologic Clinics of North America

IS - 2

ER -

Oral chemotherapy for hormone refractory prostate cancer: The University of Michigan experience

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this